Nemes Rush Group LLC Boosts Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Nemes Rush Group LLC boosted its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 93.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,224 shares of the company’s stock after purchasing an additional 7,844 shares during the period. Nemes Rush Group LLC’s holdings in MiMedx Group were worth $112,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Headlands Technologies LLC purchased a new position in MiMedx Group during the 1st quarter valued at $27,000. Isthmus Partners LLC increased its position in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after buying an additional 91,714 shares during the period. Quest Partners LLC bought a new position in MiMedx Group in the second quarter worth about $81,000. Entropy Technologies LP purchased a new stake in MiMedx Group in the first quarter worth about $99,000. Finally, Shell Asset Management Co. bought a new stake in MiMedx Group during the 1st quarter valued at approximately $113,000. Institutional investors own 79.15% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. Craig Hallum decreased their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price objective on shares of MiMedx Group in a research report on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, MiMedx Group has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

MiMedx Group stock opened at $5.83 on Monday. MiMedx Group, Inc. has a twelve month low of $5.57 and a twelve month high of $9.27. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $860.53 million, a P/E ratio of 13.25 and a beta of 1.98. The stock’s 50 day moving average is $6.53 and its 200 day moving average is $6.93.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 31st. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $87.21 million for the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. On average, equities research analysts predict that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.